Baseline and demographic characteristics
| . | Arm 1: CHAM (n = 98) . | Arm 2: control (n = 102) . | Total (N = 200) . |
|---|---|---|---|
| Sex | |||
| Female | 37 (38%) | 42 (41%) | 79 (40%) |
| Male | 61 (62%) | 60 (59%) | 121 (61%) |
| Age (y) | |||
| Median | 66 | 65 | 65 |
| Min, max | 50-84 | 50-84 | 50-84 |
| ECOG performance status | |||
| Score 0-1 | 89 (90.8%) | 93 (91.2%) | 182 (91.0%) |
| Score 2 | 9 (9.2%) | 9 (8.8%) | 18 (9.0%) |
| ELN 2017 cytogenetic risk category | |||
| Favorable | 15 (15.3%) | 15 (14.7%) | 30 (15%) |
| Intermediate | 38 (38.8%) | 41 (40.2%) | 79 (39.5%) |
| Poor | 36 (36.7%) | 36 (35.3%) | 72 (36.0%) |
| Unknown | 9 (9.2%) | 10 (9.8%) | 19 (9.5%) |
| Disease status | |||
| Relapsed | 51 (52%) | 52 (51%) | 103 (51.5%) |
| Primary refractory | 47 (48%) | 50 (49%) | 97 (48.5%) |
| Prior therapy | |||
| 7+3 | 56 (57.1%) | 58 (56.9%) | 114 (57.0%) |
| HiDAC based | 12 (12.2%) | 17 (16.7%) | 29 (14.5%) |
| HMA with/without venetoclax | 30 (30.6%) | 27 (26.5%) | 57 (28.5%) |
| Median time from initial AML diagnosis (mo) | 7.2 | 8.7 | 8.0 |
| Geographical region | |||
| United States | 49 (50.0%) | 50 (49.0%) | 99 (49.5%) |
| Europe | 41 (41.8%) | 37 (36.3%) | 78 (39.0%) |
| Rest of the world | 8 (8.2%) | 15 (14.7%) | 23 (11.5%) |
| . | Arm 1: CHAM (n = 98) . | Arm 2: control (n = 102) . | Total (N = 200) . |
|---|---|---|---|
| Sex | |||
| Female | 37 (38%) | 42 (41%) | 79 (40%) |
| Male | 61 (62%) | 60 (59%) | 121 (61%) |
| Age (y) | |||
| Median | 66 | 65 | 65 |
| Min, max | 50-84 | 50-84 | 50-84 |
| ECOG performance status | |||
| Score 0-1 | 89 (90.8%) | 93 (91.2%) | 182 (91.0%) |
| Score 2 | 9 (9.2%) | 9 (8.8%) | 18 (9.0%) |
| ELN 2017 cytogenetic risk category | |||
| Favorable | 15 (15.3%) | 15 (14.7%) | 30 (15%) |
| Intermediate | 38 (38.8%) | 41 (40.2%) | 79 (39.5%) |
| Poor | 36 (36.7%) | 36 (35.3%) | 72 (36.0%) |
| Unknown | 9 (9.2%) | 10 (9.8%) | 19 (9.5%) |
| Disease status | |||
| Relapsed | 51 (52%) | 52 (51%) | 103 (51.5%) |
| Primary refractory | 47 (48%) | 50 (49%) | 97 (48.5%) |
| Prior therapy | |||
| 7+3 | 56 (57.1%) | 58 (56.9%) | 114 (57.0%) |
| HiDAC based | 12 (12.2%) | 17 (16.7%) | 29 (14.5%) |
| HMA with/without venetoclax | 30 (30.6%) | 27 (26.5%) | 57 (28.5%) |
| Median time from initial AML diagnosis (mo) | 7.2 | 8.7 | 8.0 |
| Geographical region | |||
| United States | 49 (50.0%) | 50 (49.0%) | 99 (49.5%) |
| Europe | 41 (41.8%) | 37 (36.3%) | 78 (39.0%) |
| Rest of the world | 8 (8.2%) | 15 (14.7%) | 23 (11.5%) |
ECOG, Eastern Cooperative Oncology Group; ELN 2017, European LeukemiaNet 2017; HMA, hypomethylating agent; min, minimum; max, maximum.